BioSpace News Archive

Variant Prioritization Tool Driven by World’s Largest Curated Mutation Database

Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.

Ultragenyx Pharmaceutical Inc. announced it has promoted Erik Harris to Executive Vice President and Chief Commercial Officer, effective June 11, 2019.

Todos Medical Ltd. announced that CEO Herman Weiss, MD, MBA, FACOG, provided a corporate update and roadmap at LD Micro International Annual Invitational in Los Angelos, California.

Rozlytrek is the first tumor-agnostic medicine approved in Japan for adult and pediatric patients with NTRK fusion-positive advanced recurrent solid tumors.

The advent of increasingly more mainstream and affordable genetic testing enables powerful genetic research – but that power is directly associated with the strength and diversity of the database of genetic information available.

Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies

Galapagos NV received a transparency notification from The Capital Group Companies, Inc.

Trade tensions between Washington, D.C. and Beijing continue, but have not yet impacted the pharmaceutical products traded between the two countries. However, if the punitive tariffs continue and pharma is impacted, a third global player could step in to fill the void in both countries.

This acquisition does not affect the minority interest in NexusPharma held by Fox Chase Cancer Center (FCCC). GD3 welcomes the addition of both partners.